PE20171243A1 - Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados - Google Patents
Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionadosInfo
- Publication number
- PE20171243A1 PE20171243A1 PE2017000981A PE2017000981A PE20171243A1 PE 20171243 A1 PE20171243 A1 PE 20171243A1 PE 2017000981 A PE2017000981 A PE 2017000981A PE 2017000981 A PE2017000981 A PE 2017000981A PE 20171243 A1 PE20171243 A1 PE 20171243A1
- Authority
- PE
- Peru
- Prior art keywords
- orlistat
- obesity
- treatment
- modified release
- acarbosa
- Prior art date
Links
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 title abstract 5
- 229960001243 orlistat Drugs 0.000 title abstract 5
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 208000030159 metabolic disease Diseases 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- CEMXHAPUFJOOSV-XGWNLRGSSA-N (2r,3r,4r,5r)-4-[(2r,3r,4r,5s,6r)-5-[(2r,3r,4s,5s,6r)-3,4-dihydroxy-6-methyl-5-[[(1s,4r,5s,6s)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,5,6-tetrahydroxyhexanal Chemical compound O([C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@H]1O CEMXHAPUFJOOSV-XGWNLRGSSA-N 0.000 title 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 abstract 4
- 229960002632 acarbose Drugs 0.000 abstract 4
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 abstract 4
- 206010033307 Overweight Diseases 0.000 abstract 1
- -1 b) a second part Chemical compound 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
Se refiere a una composicion de liberacion modificada que comprende orlistat y acarbosa, que comprende partes individualmente distintas con diferentes patrones de liberacion: a) una primera parte, G1, que comprende aproximadamente (5 a 70)% p/p de la dosis total de acarbosa, b) una segunda parte, G2A, que comprende aproximadamente (30 a 95)% p/p de la dosis total de acarbosa, c) una tercera parte, G2B, que comprende aproximadamente (10 a 90)% p/p de la dosis total de orlistat, y d) una cuarta parte, G3, que comprende aproximadamente 10% p/p a aproximadamente 80% p/p de la dosis total de orlistat; y la concentracion total de acarbosa y orlistat, respectivamente, en la composicion de 100% p/p. Dicha composicion es util en el tratamiento de enfermedades metabolicas tales como obesidad, sobrepeso y diabetes tipo 2
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14198468 | 2014-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20171243A1 true PE20171243A1 (es) | 2017-08-24 |
Family
ID=52146175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000981A PE20171243A1 (es) | 2014-12-17 | 2015-12-17 | Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10561617B2 (es) |
| EP (3) | EP3943076A3 (es) |
| JP (1) | JP6607955B2 (es) |
| KR (2) | KR101937069B1 (es) |
| CN (1) | CN107405309B (es) |
| AU (1) | AU2015367422B2 (es) |
| BR (1) | BR112017012714B1 (es) |
| CA (1) | CA2970991C (es) |
| CL (1) | CL2017001574A1 (es) |
| CO (1) | CO2017005834A2 (es) |
| DK (1) | DK3233066T3 (es) |
| EA (1) | EA033448B1 (es) |
| EC (1) | ECSP17035750A (es) |
| ES (1) | ES2901122T3 (es) |
| HU (1) | HUE057093T2 (es) |
| IL (1) | IL252865B2 (es) |
| MX (3) | MX2017007493A (es) |
| MY (1) | MY195038A (es) |
| NZ (1) | NZ732241A (es) |
| PE (1) | PE20171243A1 (es) |
| PH (1) | PH12017550023A1 (es) |
| PL (1) | PL3233066T3 (es) |
| SA (1) | SA517381713B1 (es) |
| SG (1) | SG11201704470PA (es) |
| SI (1) | SI3233066T1 (es) |
| UA (1) | UA122403C2 (es) |
| WO (1) | WO2016097170A1 (es) |
| ZA (1) | ZA201704590B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017007493A (es) | 2014-12-17 | 2018-01-26 | Empros Pharma Ab | Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados. |
| CN109310640A (zh) * | 2016-06-09 | 2019-02-05 | Ds 制药动物健康株式会社 | 用于动物的缓释制剂组合物 |
| GB201803363D0 (en) | 2018-03-01 | 2018-04-18 | Sigrid Therapeutics Ab | New materials and uses thereof |
| WO2020227437A1 (en) | 2019-05-06 | 2020-11-12 | Axial Biotherapeutics, Inc. | Sustained release solid dosage forms for modulating the colonic microbiome |
| KR102508141B1 (ko) * | 2019-07-01 | 2023-03-10 | 주식회사 연세대학교 바이오헬스기술지주회사 | 하이드로겔 및 egfr 리간드를 유효성분으로 포함하는 당 배출용 조성물 |
| PL4072532T3 (pl) * | 2019-12-11 | 2024-06-10 | Evonik Operations Gmbh | Postać dawkowania do zastosowania w leczeniu lub zapobieganiu chorobie |
| CN111297826B (zh) * | 2020-04-20 | 2021-08-03 | 鲁南制药集团股份有限公司 | 一种稳定的奥利司他胶囊及其制备方法 |
| WO2022154687A1 (ru) * | 2021-01-14 | 2022-07-21 | Общество C Ограниченной Ответственностью "Новамедика" | Фармацевтическая композиция, включающая эзомепразол |
| WO2022243528A1 (en) | 2021-05-21 | 2022-11-24 | Empros Pharma Ab | Use of a composition comprising orlistat and acarbose to obtain a sustained weight loss |
| WO2022243525A1 (en) | 2021-05-21 | 2022-11-24 | Empros Pharma Ab | Synergistic effects on weight loss, improved quality of life and gastro-intestinal side effects with a composition of orlistat and acarbose |
| JP2024519926A (ja) | 2021-05-21 | 2024-05-21 | エンプロス ファーマ エービー | 過体重又は肥満について処置された対象における低減されたリバウンド効果 |
| JP2024533431A (ja) * | 2021-09-09 | 2024-09-12 | ジュニオン ラブズ ピーティーイー． リミテッド | リパーゼ阻害剤を含む高吸収性ハイドロゲル |
| JP2025538212A (ja) * | 2022-11-10 | 2025-11-26 | テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | 肝疾患又は障害を治療若しくは予防する方法 |
| CN117502631A (zh) * | 2023-12-11 | 2024-02-06 | 浙江华康药业股份有限公司 | 调节胃肠激素的甜味剂组合物及其制备方法 |
| WO2025207711A1 (en) * | 2024-03-27 | 2025-10-02 | Mayo Foundation For Medical Education And Research | Lipase inhibitor compositions and methods for treating diseases |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8101930A (nl) | 1981-04-21 | 1982-11-16 | Philips Nv | Contactinrichting voor een meeraderige kabel. |
| TW381025B (en) * | 1993-08-05 | 2000-02-01 | Hoffmann La Roche | Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor |
| WO1999026606A2 (en) * | 1997-11-25 | 1999-06-03 | Bayer Aktiengesellschaft | SUSTAINED RELEASE FORMULATIONS COMPRISING α-GLUCOSIDASE-INHIBITORS |
| DE19802700A1 (de) * | 1998-01-24 | 1999-07-29 | Bayer Ag | Verfahren zur Herstellung einer im Mund schnell zerfallenden Arzneiform, die als Wirkstoff Acarbose enthält |
| US20060240105A1 (en) * | 1998-11-02 | 2006-10-26 | Elan Corporation, Plc | Multiparticulate modified release composition |
| EA200601145A1 (ru) * | 1998-11-12 | 2009-04-28 | Смитклайн Бичам П.Л.С. | Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов |
| US6419954B1 (en) * | 2000-05-19 | 2002-07-16 | Yamanouchi Pharmaceutical Co., Ltd. | Tablets and methods for modified release of hydrophilic and other active agents |
| US6849609B2 (en) | 2001-04-10 | 2005-02-01 | James U. Morrison | Method and composition for controlled release acarbose formulations |
| WO2003009840A1 (en) * | 2001-07-24 | 2003-02-06 | Lonza Ag | Composition comprising at least one lipase inhibitor and carnitine |
| CN1296050C (zh) * | 2003-12-10 | 2007-01-24 | 浙江海正药业股份有限公司 | 阿卡波糖肠溶片及制备方法 |
| US20060229261A1 (en) * | 2005-04-12 | 2006-10-12 | John Devane | Acarbose methods and formulations for treating chronic constipation |
| FR2891459B1 (fr) * | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| EP1872777A1 (en) * | 2006-06-27 | 2008-01-02 | LEK Pharmaceuticals D.D. | Pharmaceutical composition comprising tetrahydrolipstatin |
| KR100857411B1 (ko) * | 2006-07-21 | 2008-09-08 | 한올제약주식회사 | 리파아제 저해제의 경구 투여용 방출조절 약학 제제 및이의 제조 방법 |
| US8110186B2 (en) * | 2006-09-18 | 2012-02-07 | Chelatexx, LLC | Method to maintain the efficacy of orlistat |
| CN100464754C (zh) * | 2007-03-12 | 2009-03-04 | 杭州中美华东制药有限公司 | 阿卡波糖药物组合物及其制备方法 |
| TW200841876A (en) * | 2007-04-18 | 2008-11-01 | Anchen Pharmaceuticals Taiwan Inc | Pharmaceutical composition containing orlistat |
| WO2009039157A2 (en) | 2007-09-17 | 2009-03-26 | Dr. Reddy's Laboratories Ltd. | Orlistat pharmaceutical formulations |
| WO2010065491A2 (en) * | 2008-12-01 | 2010-06-10 | Carolus Therapeutics, Inc. | Methods of treating inflammatory disorders |
| CN106924199A (zh) * | 2010-04-27 | 2017-07-07 | 拜耳知识产权有限责任公司 | 包含阿卡波糖的口腔崩解片 |
| US9314430B2 (en) * | 2010-07-05 | 2016-04-19 | Jagotec Ag | Floating gastric retentive dosage form |
| TR201100148A2 (tr) * | 2011-01-06 | 2012-07-23 | Bi̇lgi̇ç Mahmut | Stabil akarboz förmülasyonları. |
| CN102872062A (zh) | 2011-07-13 | 2013-01-16 | 鲁南制药集团股份有限公司 | 一种治疗或预防肥胖症以及代谢综合症的药物组合物 |
| MX2017007493A (es) | 2014-12-17 | 2018-01-26 | Empros Pharma Ab | Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados. |
-
2015
- 2015-12-17 MX MX2017007493A patent/MX2017007493A/es active IP Right Grant
- 2015-12-17 EP EP21181417.3A patent/EP3943076A3/en active Pending
- 2015-12-17 EA EA201791348A patent/EA033448B1/ru not_active IP Right Cessation
- 2015-12-17 CN CN201580069627.5A patent/CN107405309B/zh active Active
- 2015-12-17 BR BR112017012714-8A patent/BR112017012714B1/pt active IP Right Grant
- 2015-12-17 UA UAA201707443A patent/UA122403C2/uk unknown
- 2015-12-17 KR KR1020177019768A patent/KR101937069B1/ko active Active
- 2015-12-17 NZ NZ732241A patent/NZ732241A/en not_active IP Right Cessation
- 2015-12-17 DK DK15813822.2T patent/DK3233066T3/da active
- 2015-12-17 SG SG11201704470PA patent/SG11201704470PA/en unknown
- 2015-12-17 HU HUE15813822A patent/HUE057093T2/hu unknown
- 2015-12-17 JP JP2017550998A patent/JP6607955B2/ja active Active
- 2015-12-17 US US15/536,334 patent/US10561617B2/en active Active
- 2015-12-17 KR KR1020187038218A patent/KR102094631B1/ko active Active
- 2015-12-17 PE PE2017000981A patent/PE20171243A1/es unknown
- 2015-12-17 ES ES15813822T patent/ES2901122T3/es active Active
- 2015-12-17 PL PL15813822T patent/PL3233066T3/pl unknown
- 2015-12-17 CA CA2970991A patent/CA2970991C/en active Active
- 2015-12-17 MX MX2019001376A patent/MX382196B/es unknown
- 2015-12-17 SI SI201531755T patent/SI3233066T1/sl unknown
- 2015-12-17 EP EP15813822.2A patent/EP3233066B1/en active Active
- 2015-12-17 EP EP24163588.7A patent/EP4364743A3/en active Pending
- 2015-12-17 MY MYPI2017702204A patent/MY195038A/en unknown
- 2015-12-17 WO PCT/EP2015/080265 patent/WO2016097170A1/en not_active Ceased
- 2015-12-17 AU AU2015367422A patent/AU2015367422B2/en active Active
- 2015-12-17 IL IL252865A patent/IL252865B2/en unknown
-
2017
- 2017-06-02 PH PH12017550023A patent/PH12017550023A1/en unknown
- 2017-06-08 MX MX2021003905A patent/MX2021003905A/es unknown
- 2017-06-08 EC ECIEPI201735750A patent/ECSP17035750A/es unknown
- 2017-06-12 SA SA517381713A patent/SA517381713B1/ar unknown
- 2017-06-14 CO CONC2017/0005834A patent/CO2017005834A2/es unknown
- 2017-06-16 CL CL2017001574A patent/CL2017001574A1/es unknown
- 2017-07-07 ZA ZA2017/04590A patent/ZA201704590B/en unknown
-
2020
- 2020-01-24 US US16/752,267 patent/US11975105B2/en active Active
-
2024
- 2024-04-10 US US18/631,545 patent/US20240342096A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20171243A1 (es) | Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados | |
| CO2017011851A2 (es) | Compuestos novedosos | |
| CL2019000575A1 (es) | Análogos de amilina. | |
| DOP2015000245A (es) | Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos | |
| NI201600018A (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| NI201600115A (es) | Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| CR20160518A (es) | Compuestos para tratar atrofia muscular espinal | |
| MX2020003112A (es) | Composiciones de biguanida y metodos para tratar trastornos metabolicos. | |
| BR112017004741A2 (pt) | compostos e composições como inibidores da raf quinase | |
| DOP2016000170A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
| NI202000029A (es) | Amidas de imidazopiridina sustituidas y su uso | |
| CL2017000845A1 (es) | Inhibidores de gingipaina de lisina | |
| CO2019011227A2 (es) | N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso | |
| EA201690191A1 (ru) | Фармацевтическая композиция для замедленного высвобождения ланреотида | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| CL2016000884A1 (es) | Derivados de piperazina y su uso como medicamento. | |
| CO2017004785A2 (es) | N-[4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il]-2-metilpiridin-5-carboxamida o una sal farmacéutica como antagonista del receptor a2a | |
| CO2019008657A2 (es) | Composición intranasal que comprende betahistina | |
| DOP2016000325A (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas | |
| MX2019009909A (es) | Composiciones farmaceuticas para terapia de combinacion. | |
| DOP2015000290A (es) | Benzoxazoles sustituidos | |
| CL2018001236A1 (es) | Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo. |